Table 4 Association of demographic, clinical and therapeutic parameters and PROs with WHO-5, PHQ-9 and GAD-7 scores
| Â | WHO-5 score | PHQ-9 score | GAD-7 score | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
beta | 95% CI | p value | betaST | beta | 95% CI | p value | betaST | beta | 95% CI | p value | betaST | |
Female | -4.17 | -8.06; -0.28 | 0.036 | -0.08 | 1.65 | 0.87; 2.43 | < 0.001 | 0.17 | 1.52 | 0.79; 2.24 | < 0.001 | 0.17 |
Age | -0.94 | -1.89; 0.01 | 0.052 | -0.08 | 0.20 | 0.01; 0.40 | 0.037 | 0.08 | 0.14 | -0.04; 0.31 | 0.134 | 0.06 |
JIA | (ref) | Â | Â | Â | (ref) | Â | Â | Â | (ref) | Â | Â | Â |
SLE | 3.31 | -3.88; 10.50 | 0.367 | 0.04 | -0.41 | -1.87; 1.05 | 0.580 | -0.02 | -0.21 | -1.54; 1.13 | 0.761 | -0.01 |
JDM | 5.13 | -7.77; 18.04 | 0.435 | 0.03 | -0.64 | -3.41; 2.13 | 0.650 | -0.02 | -0.25 | -2.84; 2.35 | 0.853 | -0.01 |
PhGA | -0.78 | -1.95; 0.40 | 0.196 | -0.06 | -0.11 | -0.36; 0.13 | 0.375 | -0.04 | 0.00 | -0.23; 0.22 | 0.984 | -0.01 |
MTX | -2.04 | -6.01; 1.94 | 0.315 | -0.04 | 0.50 | -0.30; 1.29 | 0.223 | 0.05 | 0.64 | -0.10; 1.38 | 0.088 | 0.07 |
bDMARD | 1.76 | -2.24; 5.76 | 0.389 | 0.03 | 0.16 | -0.64; 0.96 | 0.692 | 0.02 | -0.08 | -0.82; 0.66 | 0.826 | -0.01 |
PGA | -3.05 | -3.91; -2.19 | < 0.001 | -0.32 | 0.58 | 0.41; 0.75 | < 0.001 | 0.30 | 0.43 | 0.27; 0.58 | < 0.001 | 0.24 |
CHAQ | -5.33 | -9.91; -0.75 | 0.023 | -0.10 | 1.68 | 0.72; 2.64 | 0.001 | 0.16 | 1.65 | 0.81; 2.50 | < 0.001 | 0.18 |